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Abstract
Background: Prostate cancer is the most commonly diagnosed malignancy in men and is thought
to arise as a result of endogenous oxidative stress in the face of compromised carcinogen defenses.
We tested whether carcinogen defense (phase 2) enzymes could be induced in the prostate tissues
of rats after oral feeding of candidate phase 2 enzyme inducing compounds.
Methods: Male F344 rats were gavage fed sulforaphane, β-naphthoflavone, curcumin, dimethyl
fumarate or vehicle control over five days, and on the sixth day, prostate, liver, kidney and bladder
tissues were harvested. Cytosolic enzyme activities of nicotinamide quinone oxidoreductase
(NQO1), total glutathione transferase (using DCNB) and mu-class glutathione transferase (using
CDNB) were determined in the treated and control animals and compared.
Results:  In prostatic tissues, sulforaphane produced modest but significant increases in the
enzymatic activities of NQO1, total GST and GST-mu compared to control animals. β-
naphthoflavone significantly increased NQO1 and GST-mu activities and curcumin increased total
GST and GST-mu enzymatic activities. Dimethyl fumarate did not significantly increase prostatic
phase 2 enzyme activity. Compared to control animals, sulforaphane also significantly induced
NQO1 or total GST enzyme activity in the liver, kidney and, most significantly, in the bladder
tissues. All compounds were well tolerated over the course of the gavage feedings.
Conclusion: Orally administered compounds will induce modestly phase 2 enzyme activity in the
prostate although the significance of this degree of induction is unknown. The 4 different
compounds also altered phase 2 enzyme activity to different degrees in different tissue types. Orally
administered sulforaphane potently induces phase 2 enzymes in bladder tissues and should be
investigated as a bladder cancer preventive agent.
Background
The most commonly diagnosed cancer among men, pros-
tate cancer will account for nearly 30,000 deaths in the
United States in 2005 and cause countless men to suffer
significant morbidity [1]. Accumulating evidence impli-
cates oxidative damage, possibly due to prostatic inflam-
mation, as an important contributor to prostate
carcinogenesis [2]. Some human prostate cells appear to
acquire increased susceptibility to oxidative DNA damage
because they lack expression of glutathione S-transferase-
π (GSTP1) due to somatically acquired methylation of
deoxycytidine residues in "CpG islands" in the 5'-regula-
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tory region of the GSTP1 gene early in prostate carcino-
genesis [3-6]. GSTP1 is an important member of the class
of enzymes (phase 2 enzymes) that protect cells against
electrophilic compounds, including many carcinogens
and oxidative species [7]. Strategies to induce the expres-
sion and activity of phase 2 enzymes have been shown to
protect against carcinogenesis in a variety of organ sites
and across several species [8,9]. Since prostate cancer
appears to be uniquely deficient in the phase 2 enzyme
GSTP1, a rational prevention strategy might be to com-
pensate for GSTP1 loss by global induction of phase 2
enzymes within the prostate.
A number of compounds effective at inducing phase 2
enzyme activity have been identified by screening for
nicotinomide quinone oxidoreductase (NQO1) enzy-
matic induction in the Hepa 1c1c7 cell line [10-12]. Com-
pounds effective at inducing phase 2 enzymatic activity in
Hepa 1c1c7 cells in vitro have been found to be effective at
inducing the phase 2 enzyme response in vivo, and several
of these compounds have also been demonstrated to pre-
vent against carcinogen induced tumors in animal models
[11,13]. However, compounds that induce NQO1 activity
in liver-derived Hepa 1c1c7 cells do not always produce
induction in liver cells in vivo, and can vary in their effec-
tiveness at inducing phase 2 enzymes in different tissues
[14-16]. For instance, both tert-butyl-4-hydroxyanisole
(BHA) and dimethyl fumarate are effective at inducing
NQO1 activity in Hepa 1c1c7 cells in vitro, but in CD-1
mice, only BHA induces NQO1 activity in the liver (6-
fold), in addition to the lung and kidney (2-fold), but not
in the stomach and colon [17]. Dimethyl fumarate, on the
other hand, induces NQO1 enzymatic activity in the
forestomach, small intestine, kidneys and lungs, but pro-
duces little change in NQO1 activity in the liver [11].
To identify compounds effective at inducing phase 2
enzymes in human prostate cells, we have carried out a
comprehensive screen of candidate phase 2 enzyme
inducing agents in human prostate cancer cells in vitro and
identified compounds from several chemical classes that
were effective at producing modest increases in NQO1
enzymatic activity [18]. Notably, the pattern of NQO1
induction across compounds differed between prostate
cancer cell lines and a human liver cell line, suggesting
that there could be significant differences in the response
of prostate cells to phase 2 enzyme inducing agents com-
pared to other tissue types. We also have demonstrated
that sulforaphane, an isothiocyanate found in cruciferous
vegetables, induces NQO1, glutathione synthetic
enzymes and glutathione transferases in several human
prostate cancer cells [19].
Although we have identified compounds effective at
inducing phase 2 enzymes in prostate cells in vitro, the
possibility of inducing phase 2 enzyme response in the
prostate in vivo has not been tested. We selected 4 candi-
date phase 2 enzyme inducing agents effective in prostate
cells in vitro and tested whether they could induce phase 2
enzyme enzymatic activity in the prostates of F344 rats in
vivo. After 5 days of gavage feeding with each of candidate
compounds or vehicle alone, global GST activity, isozyme
GST-mu and NQO1 activity were assessed in the prostate,
liver, kidney and bladder tissues of male rats.
Methods
Materials
Purified sulforaphane was obtained from LKT labs (St.
Paul, MN), curcumin, β-naphthoflavone (BNF), propyl-
ene glycol, dimethyl fumarate (DMF), 1,2-dichloro-4-
nitrobenzene (DCNB) and 1-chloro-2,4-dinitrobenzene
(CDNB) from Sigma-Aldrich Inc. (St. Louis, MO), and
AIN 76A diet from Research Diets (New Brunswick, NJ).
Male F-344 rats were purchased from Jackson labs (Bar
Harbor, ME).
Treatment of animals and tissue collection
Eight-week-old male F344 rats were housed in microisola-
tor cages in groups of 2 or 3 animals per cage. Mean body
weight of the rats was 188 ± 4.0 g at the start of the study,
and animals had access to AIN 76A diet and water ad libi-
tum over the duration of the study. Animals were ran-
domly divided into 5 groups of 10 animals corresponding
to each of the 4 test compounds and a control group that
received vehicle alone. All compounds were mixed fresh
each day by either dissolving or suspending them in 100
μl propylene glycol at the following doses: sulforaphane
50 mg/Kg/day [13], curcumin 45 mg/Kg/day [20], β-
naphthoflavone 41 mg/Kg/day [15] and dimethyl fuma-
rate 37.5 mg/Kg/day [11]. Doses were chosen that had
been reported to be non-toxic and effective at inducing
phase 2 enzymes in other model systems. Compounds or
propylene glycol were administered in a single dose once
a day by gavage at doses corrected for the body weight of
each animal. The gavage feeding was carried out after the
rats received isofluorane inhalation anesthesia and
involved minimal trauma. Animals recovered rapidly
from this agent and were observed until fully awake in
their cages. All rats were monitored for infection or toxic-
ity to prevent suffering, and there were no obvious signs
of discomfort, distress, or pain over the duration of the
study. One animal in the sulforaphane group died shortly
after the first gavage feeding, and another died after the
second feeding, both apparently due to aspiration of the
dose. Necropsy did not reveal any gross abnormalities of
any organs. On the morning of the sixth day, the rats were
sacrificed by CO2 asphyxiation approximately 24 hours
after the last dose.BMC Cancer 2006, 6:62 http://www.biomedcentral.com/1471-2407/6/62
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The rats were housed at the Animal Care Facility at the
Stanford University School of Medicine in compliance
with PHS Policies on Humane Care and Use of Laboratory
Animals. All work was carried out under Administrative
Panel on Laboratory Animal Care approved protocols. All
animals were under strict veterinarian care of the Depart-
ment of Comparative Medicine in compliance with all
Federal and State regulations to assure proper and
humane treatment.
Collection of tissues and preparation of cytosol
The liver, kidneys, bladder and the prostate tissues were
removed, weighed and snap frozen in liquid Nitrogen,
and stored in -80°C until processed for the enzyme assays.
Cytosols were prepared from the harvested tissues by
homogenization in 0.25 M sucrose and centrifugation at
5000 × g for 20 minutes at -4°C. 0.2 volume of 0.1 M
CaCl2 in 0.25 M sucrose was added to the supernatant
and, after incubation on ice for 30 minutes, samples are
centrifuged at 15,000 × g at -4°C for 20 minutes.
Enzyme assays
Total glutathione transferase enzyme activity was deter-
mined using 1,2-dichloro-4-nitrobenzene (DCNB) and
GST mu activity was measured using 1-chloro-2,4-dini-
trobenzene (CDNB) according to the procedure of Habig
et al. [21]. Cytosols (50 μl) were added to 150 μl 0.1 M
phosphate buffer pH 6.5 buffer with 1 mM GSH, 1 mM
CDNB or DCNB, and 1% BSA, mixed and optical absorb-
ance was read at 340 nm at 30 sec intervals over 5 min-
utes. Because of high specific activity, liver samples were
diluted 5-fold. GST mu activity was not measured in the
bladder samples. Quinone reductase activity was deter-
mined by the rate of the NADPH-dependent, menadione-
coupled reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide in 96-well microtire plates
as described previously [18,19,22]. Enzyme activities were
normalized to total cytosolic protein measured according
to the Bradford method [23]. All assays and protein meas-
urements were performed in triplicate. Mean enzyme spe-
cific activities for tissues from animals in each group were
calculated and the fold-induction enzyme specific activi-
ties determined by taking a ratio of log-transformed
inducer-treated enzyme activities to the controls. The 95%
confidence intervals for the fold-induction of enzyme spe-
cific activities of the inducer-treated animals compared to
controls were calculated on log-transformed data and the
results back-transformed to the fold-scale.
Results
All compounds were well tolerated by the animals and
there was no apparent toxicity over the duration of the
study. None of the compounds affected the relative
weights of the prostate, kidneys, liver or bladder after gav-
age feedings over 5 days. Body weights did not differ sig-
nificantly between the groups fed candidate compounds
and the control animals (Table 1). However, compared to
initial body weights, there was an 8% decrease in body
weight in the sulforaphane treated group after 5 days (P =
0.03), and non-significant increases (1–5%) in the body
weights of the other 4 groups.
Sulforaphane treated animals showed significantly higher
NQO1, total GST and GST-mu enzymatic activities in
their prostate tissues compared to control animals (Figure
1 and Tables 2, 3 and 4) although the degree if increase
was modest (1.2- to 1.8-fold). Compared to controls, β-
naphthoflavone treated animals showed small, statisti-
cally significant higher levels of NQO1 activity, no differ-
ences in total GST enzymatic activity, and moderately
elevated GST-mu activity in the prostate. Curcumin
treated animals also displayed significantly higher total
GST and GST-mu activities in prostate tissues over control
levels, although, again, the differences were modest. Pros-
tate tissues from dimethyl fumarate treated animals did
not show differences in NQO1, total GST or GST-mu
enzymatic activities compared to controls.
The effects of sulforaphane, β-naphthoflavone, curcumin
and dimethyl fumarate on phase 2 enzyme activity in the
liver, kidney and bladder in many ways paralleled that
observed in the prostate. Liver tissues from animals
treated with sulforaphane, β-naphthoflavone, and to a
lesser extent dimethyl fumarate, showed modestly higher
NQO1 enzyme activity compared control animals, while
curcumin appeared to have no effect (Figure 2A and Table
Table 1: Final body weight and relative organ weights of male control and inducer treated F344 rats
Sulforaphane BNF Curcumin DMF Control
Number 8 1 01 01 0 1 0
Final body weight (g) 177.5 ± 10.35 * 190.3 ± 12.56 184.4 ± 13.59 190.2 ± 15.65 195.8 ± 8.52
Liver (%) 4.13 ± 0.22 4.84 ± 0.27 4.60 ± 0.22 4.71 ± 0.37 4.96 ± 0.22
Kidney (%) 0.86 ± 0.07 0.97 ± 0.04 0.91 ± 0.04 0.93 ± 0.04 0.88 ± 0.04
Prostate (%) 0.15 ± 0.02 0.17 ± 0.04 0.15 ± 0.03 0.15 ± 0.03 0.17 ± 0.03
Bladder (%) 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.02 ± 0.01
Data are mean ± SEM values. * = P < 0.05 vs. initial body weightBMC Cancer 2006, 6:62 http://www.biomedcentral.com/1471-2407/6/62
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2). All four compounds resulted in significantly higher
total glutathione transferase enzymatic activity in the liv-
ers of treated animals compared to controls, and sulforap-
hane produced the greatest elevation (Figure 2B and Table
3). Somewhat paradoxically GST-mu activity levels in the
liver did not differ significantly between animals treated
with inducer compounds and controls and were actually
lower in sulforaphane-treated animals (Table 4). NQO1
enzymatic activity was also higher in the kidney tissues of
the sulforaphane, β-naphthoflavone and dimethyl fuma-
rate treated animals compared to controls, while NQO1
enzyme activities in curcumin treated animals matched
those seen in controls (Figure 2A and Table 2). On the
other hand, kidney levels of total GST and GST-mu enzy-
matic activity were no different between the 4 inducer
compound treated groups and the controls except for
induction of GST-mu by curcumin (Figure 2B and Tables
3 and 4). Interestingly, NQO1 and total glutathione trans-
ferase enzymatic activities were dramatically higher in the
bladder tissues of the sulforaphane treated animals com-
pared to the controls (4.4-fold and 4.2-fold, respectively)
(Figure 2A and 2B, and Tables 2 and 3). NQO1 enzyme
activities in bladder tissues were also significantly
increased over controls in the animals treated with β-
naphthoflavone, curcumin and dimethyl fumarate,
although the differences were not as marked as in the sul-
foraphane-treated animals. Total GST enzyme specific
activities did not differ significantly from control bladder
tissues for any of the three compounds.
Discussion
We have previously identified compounds effective at pro-
ducing modest increases in NQO1 enzymatic activity in
human prostate cells in vitro [18,19] and selected 4 com-
pounds for testing whether they could produce induction
of phase 2 enzyme activity in vivo. We selected sulforap-
hane, dimethyl fumarate and cucumin since they were
among the most potent NQO1 inducing agents in pros-
tate cells in vitro, have been reported to be monofunc-
tional inducers (i.e. induce phase 2 enzymes primarily),
and have been administered to animals without toxicity
previously [11,13,20]. β-naphthoflavone, a bifunctional
(phase 1 and 2) enzyme inducing compound, was
selected because of its documented ability to induce phase
2 enzyme activity in rodent tissues in vivo and for compar-
ison to the other compounds since it increased NQO1
activity to a lesser degree in the prostate cells in vitro [15].
We have demonstrated that orally administered agents
can produce modest increases in phase 2 enzyme activity
in prostate tissues in vivo. We have shown previously that
sulforaphane, curcumin, dimethyl fumarate and, to a
lesser degree, β-naphthoflavone will induce modest
increases NQO1 enzymatic activity in prostate cancer cells
in vitro [18,19]. Effective induction in vivo depends on can-
didate phase 2 enzyme inducing compounds being
absorbed from the gastrointestinal tract, and those com-
pounds or their active metabolites reaching the prostate,
being absorbed from the circulation and acting in prostate
cells in the context of their physiological environment.
Table 2: Mean specific activity of NQO1 in nmol/min/mg of protein (Ratio of the treated/control enzyme specific activities, 95% 
Confidence Intervals)
Sulforaphane BNF Curcumin DMF Control
Liver 69 (2.5, 2.2–2.9)* 43 (1.6, 1.5–1.7)* 34 (1.2, 0.99–1.6) 32 (1.2, 1.04–1.3)* 27
Kidney 41 (2.5, 2.2–2.9)* 26 (1.6, 1.5–1.7)* 20 (1.2, 0.99–1.6) 19 (1.2, 1.04–1.3)* 16
Prostate 103 (1.6, 1.4–1.9)* 80 (1.3, 1.1–1.5)* 72 (1.2, 0.95–1.4) 65 (1.04, 0.85–1.3) 63
Bladder 26 (4.4, 4.2–4.7)* 9.0 (1.5,1.2–1.8)* 10 (1.8, 1.4–2.1)* 10 (1.8. 1.4–2.2)* 6.0
Data are mean values of 8–10 animals in each group
* = P < 0.05 based on confidence intervals of the ratio of treated vs. control NQO1 specific activities
Fold-induction of phase 2 enzymes NQO1, total GST and  GST-mu activity in the prostate tissue of male F344 rats  treated for 5 days with 50 mg/Kg Sulforaphane (n = 8), 45  mg/Kg Curcumin (n = 10), 41 mg/Kg β-naphthoflavone (n =  10) and 37.5 mg/Kg Dimethylfumarate (n = 10) Figure 1
Fold-induction of phase 2 enzymes NQO1, total GST and 
GST-mu activity in the prostate tissue of male F344 rats 
treated for 5 days with 50 mg/Kg Sulforaphane (n = 8), 45 
mg/Kg Curcumin (n = 10), 41 mg/Kg β-naphthoflavone (n = 
10) and 37.5 mg/Kg Dimethylfumarate (n = 10). Fold-induc-
tion is the ratio of specific activity of treated against control 
animals (n = 10) and is plotted on a log scale. Data represent 
average of assays in triplicate. Data are mean and 95% confi-
dence intervals of animals in each group.
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Our finding of even modest induction of phase 2 enzyme
activity implies that each of these pharmacokinetic con-
straints can be overcome, and suggests that phase 2
enzyme induction by orally administered agents could
represent a possible prostate cancer prevention strategy.
However, whether the modest increases in phase 2
enzyme activity induced by sulforaphane, dimethyl fuma-
rate, cucumin and β-naphthoflavone are sufficient to pre-
vent prostate cancer is unknown and remains to be tested.
The F344 rat will develop prostate adenocarcinoma after
chronic administration of 2-amino-1-methyl-6-phe-
nylimidazo [4,5-b]pyridine (PhIP) and is one of the few
carcinogen-induced animal models of prostate cancer
[24]. We selected this strain of rats to test to the possibility
of phase 2 enzyme induction in the prostate as a prelude
to future experiments designed to test whether phase 2
enzyme induction in the prostate could prevent PhIP-
induced prostate cancers. The degree of increase of
NQO1, total GST and GST-mu enzymatic activities in the
prostate tissues we observed was modest, and lower than
that reported in other model systems where phase 2
enzyme inducing compounds have been documented to
prevent carcinogenesis [25]. However, in man, prostate
cancer develops over decades, raising the possibility that
chronic, low-level phase 2 enzyme induction might be
sufficient to prevent the disease. Furthermore, modest
induction of phase 2 enzymes (NQO1 and total GST), vir-
tually identical to those reported in the present study,
have been observed in the liver tissues of F344 rats treated
with sulforaphane and sulforaphane nitrile derived from
cruciferous vegetables [26]. Cruciferous vegetables will
decrease the incidence preneoplastic lesions in the colon
and liver when fed simultaneously with the carcinogen 2-
amino-3methylimidazo [4,5-f]quinoline (IQ) to F344
rats [27]. Therefore, even relatively modest induction of
phase 2 enzymatic activity can be sufficient to protect
against carcinogenesis. Whether similar protection against
prostatic carcinoma will occur requires further testing. The
finding that consumption of cruciferous vegetables has
been associated with a decreased risk of subsequent pros-
tate cancer diagnosis, coupled with the ability of orally
administered sulforaphane to induce phase 2 enzyme
activity in the prostate, suggests that phase 2 enzyme
induction within the prostate is a potential prostate cancer
preventive strategy and sulforaphane is a candidate pre-
ventive agent [28,29].
In agreement with previous observations, we found that
each compound showed differing efficacy at inducing
phase 2 enzyme activity in different tissue types. The kid-
ney, for instance, showed little induction of the glutath-
ione transferases, while the GSTs were readily induced in
the liver, bladder and prostate. Prochaska et al. have
reported that the induction patterns of derivatives of tert-
butyl-4-hydroxyanisole (BHA) varied in their efficacy of
phase 2 enzyme induction, differed in the spectrum
enzymes they each induced and differed in their effective-
ness between the liver, esophagus, forestomach, colon,
kidney and lung [17]. Similarly, Spencer et al. found that
in CD-1 mice, dimethyl fumarate induced NQO1 enzy-
matic activity in the forestomach, small intestine, kidneys
and lungs, but failed to induce NQO1 activity in the liver,
similar to our findings in the F344 rat [11]. They also
Table 4: Specific activity of GSTmu in nmol/min/mg of protein (Ratio of the treated/control enzyme specific activities, 95% Confidence 
Intervals)
Sulforaphane BNF Curcumin DMF Control
Liver 0.09 (0.39, 0.25–0.62)* 0.20 (0.87, 0.71–1.1) 0.23 (1.0, 0.79–1.3) 0.29 (1.3, 1.0–1.6) 0.23
Kidney 0.06 (3.0, 0.92–9.7) 0.03 (1.5, 0.46–4.9) 0.21 (10, 3.2–34)* 0.02 (1.0, 0.25–4.0) 0.02
Prostate 0.73 (1.9, 1.4–2.4)* 0.76 (1.9, 1.5–2.5)* 0.67 (1.7,1.4–2.1)* 0.34 (0.87, 0.69–1.1) 0.39
Data are mean values of 8–10 animals in each group
* = P < 0.05 based on confidence intervals of the ratio of treated vs. control GST mu specific activities
Table 3: Mean specific activity of Total GST in nmol/min/mg of protein (Ratio of the treated/control enzyme specific activities, 95% 
Confidence Intervals)
Sulforaphane BNF Curcumin DMF Control
Liver 956 (1.6, 1.4–1.7)* 815 (1.4, 1.2–1.5)* 739 (1.2, 1.1–1.4)* 679 (1.1, 1.03–1.2)* 602
Kidney 92.5 (1.2, 1.0–1.3) 80 (1.0, 0.77–1.3) 65 (0.81, 0.67–1.0) 89 (1.1, 0.96–1.3) 81
Prostate 6.7 (1.2, 1.1–1.5)* 5.7 (1.06, 1.0–1.1) 6.9 (1.3,1.2–1.4)* 7.0 (1.3, 1.0–1.7) 5.4
Bladder 0.78 (4.2, 3.6–4.9)* 0.26 (1.4, 0.81–2.3) 0.28 (1.5, 0.96–2.3) 0.29 (1.5, 0.99–2.4) 0.19
Data are mean values of 8–10 animals in each group
* = P < 0.05 based on confidence intervals of the ratio of treated vs. control total GST specific activitiesBMC Cancer 2006, 6:62 http://www.biomedcentral.com/1471-2407/6/62
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Fold-induction in NQO1 (A) and total GST (B) enzyme activities in the liver, kidney and bladder tissues of male F344 rats  treated for 5 days with 50 mg/Kg Sulforaphane (n = 8), 45 mg/Kg Curcumin (n = 10), 41 mg/Kg β-naphthoflavone (n = 10) and  37.5 mg/Kg Dimethylfumarate (n = 10) Figure 2
Fold-induction in NQO1 (A) and total GST (B) enzyme activities in the liver, kidney and bladder tissues of male F344 rats 
treated for 5 days with 50 mg/Kg Sulforaphane (n = 8), 45 mg/Kg Curcumin (n = 10), 41 mg/Kg β-naphthoflavone (n = 10) and 
37.5 mg/Kg Dimethylfumarate (n = 10). Fold-induction is the ratio of specific activity of treated against control animals (n = 10) 
and is plotted on a log scale. Data represent the average of assays in triplicate. Data are mean 95% confidence intervals of ani-
mals in each group.
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found that the patterns of induction of total GST, GST-
mu, and NQO1 enzymatic activities differed between
compounds and by tissue type. Van Lieshout et al. have
also described differences in phase 2 enzyme responsive-
ness in the tissues of Wistar rats after treatment oltipraz, α-
tocopherol,  β-carotene, and phenethyl isothiocyanate
[16].
The reasons for the differences in the responsiveness of
phase 2 enzymes between tissues are currently unknown,
but likely are a reflection of tissue-specific expression of
transcriptional regulators or enzyme cofactors. The differ-
ence in responsiveness between tissues does have impor-
tant implications in the design and interpretation of
preventive intervention trials involving phase 2 enzyme
induction. For instance, cancers that arise from the oral
ingestion of carcinogens, such as the 9,10-dimethyl-1,2-
benzanthracene rat model of breast cancer or aflatoxin-
induced hepatocellular carcinomas in man, might best be
prevented by oral ingestion of agents that will induce
phase 2 enzymes and inactivate these carcinogens in the
gut and liver [13,30,31]. However, accumulating evidence
suggests that for prostate cancer induction of phase 2
enzymes within the prostate might best protect against car-
cinogenesis.
No environmental carcinogens have been identified as
causing human prostate cancer. Accumulating evidence
implicates endogenous oxidative damage as one impor-
tant contributor to prostate carcinogenesis [2]. Prostate
cancer increases with age and may be related to inflamma-
tory conditions of the prostate such as prostatitis [32].
Androgens are a known requisite to prostate cancer devel-
opment. Ripple et al. have demonstrated that treatment of
the prostate cancer cell line LNCaP with androgens pro-
duces a burst of oxidative stress in these cells with genera-
tion of reactive oxygen species, increased lipid
peroxidation and a depletion of intracellular glutathione
stores [33-35]. Furthermore, Malins et al. have described
progressive alterations in DNA structure between normal,
BPH and cancerous prostate tissues due to oxidative dam-
age to the DNA template be hydroxyl free radical [36-38].
Two genes recently identified as conferring increased risk
to prostate cancer in families (RNASEL and MSR2) partic-
ipate in the response to infection and inflammation
[39,40]. Mice engineered to not express RNASEL, for
instance, are more susceptible to overwhelming bacterial
infections [41]. Finally, most compounds thus far impli-
cated as prostate cancer preventive agents act as potent
antioxidants including lycopene, selenium (essential to
glutathione peroxidase activity), and vitamin E [42-44].
The early and near universal loss of expression of the
phase 2 enzyme GSTP1 likely renders prostate cells sus-
ceptible to local oxidative damage and transformation.
GSTP1 knock-out mice treated with the polycyclic aro-
matic hydrocarbon 7,12-dimethylbenz anthracene and
the tumor promoting agent 12-O-tetradecanoylphorbol-
13-acetate show increased numbers and earlier onset of
skin papillomas demonstrating that loss of expression of
a single GST can contribute to carcinogenesis [45]. Since
prostate cancer arises with a long latency in the context of
local oxidative damage coupled with an intrinsic defect in
carcinogen defenses, local induction of phase 2 enzymatic
activity, even to a modest degree, could be a promising
preventive strategy. Since prostate cancer develops over
decades, chronic, low-level, local induction of carcinogen
defenses, possibly through diet-derived agents such as sul-
foraphane, could represent a modest, non-toxic interven-
tion strategy for prevention of prostate cancer, particularly
for individuals at risk for the disease.
One notable finding was the significant induction of total
GST and NQO1 enzymatic activities in bladder tissues of
the F344 rats. Several environmental carcinogens have
been linked to bladder cancer including polyaromatic
hydrocarbons in tobacco smoke and aniline dyes [46].
Epidemiological studies have demonstrated that con-
sumption of cruciferous vegetables is associated with a
decreased risk of bladder cancer [47]. Sulforaphane levels
peak in the serum 1–2 hours after ingestion and are
cleared relatively rapidly by excretion into the urine [48].
The substantial phase 2 enzyme induction of the bladder
tissues could be due to the presence of sulforaphane or its
active metabolites at relatively high concentrations over
prolonged time periods while they are retained in the
bladder. Munday and Munday have found similar induc-
tion of NQO1 and GST activity in the bladder tissues of
female Sprague-Dawley rats after oral feedings of sulforap-
hane and several other isothiocyanates derived from cru-
ciferous vegetables [49]. Together, these data strongly
suggest that sulforaphane and other isothiocyanates could
represent promising candidate bladder cancer preventive
agents.
Our study has several shortcomings. We arbitrarily
selected a single daily dosing schedule based on prior
studies in the literature. It is possible that other dosing
schedules, perhaps different for each compound, could
produce greater phase 2 enzyme induction [50]. In addi-
tion, measurement of phase 2 enzyme activity occurred 24
hours following the last dose of each compound. The
serum half-life of sulforaphane is between 1–2 hours and
it is possible that measurement of phase 2 enzyme activity
at times less than 24 hours would reveal greater induction
of enzymatic activity [48]. Finally, all animals were given
isofluorane anesthesia at the time of gavage feeding, and
the anesthesia could have altered phase 2 enzyme activity
in the tissues. However, since both the inducer compound
treated animals and controls were treated identically, theBMC Cancer 2006, 6:62 http://www.biomedcentral.com/1471-2407/6/62
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relative levels of phase 2 enzyme activity should not have
been affected.
Conclusion
We have demonstrated the possibility of inducing phase 2
enzymatic activity in the prostate tissues of F344 rats in
vivo after oral feeding of several candidate phase 2 enzyme
inducing agents. Our findings set the stage for further test-
ing of phase 2 enzyme inducing agents in prostate cancer
prevention. A first step will be to test whether phase 2
enzyme induction in the prostate will prevent prostatic
cancers in animal models. If successful, additional work
will be necessary to identify the phase 2 enzymes critical
in cancer protection so that they can be monitored as
biomarkers of effectiveness in clinical trials.
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